CONCETTA CRISCOLA: Open Payments
NPI 1487437976 · HAMDEN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$549 in 26 payments from 13 companies in 2025. Trend: 2023 $763 · 2024 $1,293 · 2025 $549
Food & beverage: $549
| Company | Payments | Amount |
|---|---|---|
| Ardelyx, Inc. | 4 | $96 |
| AstraZeneca Pharmaceuticals LP | 3 | $78 |
| Otsuka America Pharmaceutical, Inc. | 4 | $66 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $65 |
| Lilly USA, LLC | 2 | $40 |
| PFIZER INC. | 2 | $40 |
| GlaxoSmithKline, LLC. | 2 | $37 |
| Astellas Pharma US Inc | 1 | $25 |
| Novartis Pharmaceuticals Corporation | 1 | $24 |
| ABBVIE INC. | 1 | $23 |
Products named: IBSRELA, REXULTI, XIFAXAN, BREZTRI, PAXLOVID, NUCALA, AIRSUPRA, Veozah.
Industry payments across CT — which companies pay providers there.
